Raffles Medical Group (RMG) is collaborating with biotech start-up NalaGenetics to offer pre-emptive pharmacogenomics testing at its hospital. It is the first hospital in Singapore to provide such a service.
About the Study
Pharmacogenomics is the study of a panel of genes that affect how your body responds to certain medication. Pre-emptive pharmacogenomics testing on a healthy person can be used to discover whether a person is likely to respond well or develop adverse drug reactions (ADRs) to certain medications. The test results could then be used to guide doctors on the choice and dosage of medicine to improve patient outcome.
The collaboration between RMG and NalaGenetics involves the recruitment of 500 patients to participate in a pilot study on pre-emptive pharmacogenomics testing and covers a range of chronic prescriptions in cardiovascular, psychiatry and pain, among others.
What Participation Involves
Eligible participants will have their genetic samples collected via a non-invasive buccal swab at Raffles Hospital Singapore, which will then be tested by NalaGenetics in its laboratory. The test will be integrated into the participants’ electronic medical records at RMG.
There is no cost involved to participate in the study.
Recruitment Details
Recruitment period:
NOW until June 2023 (Mon-Fri: 9am to 4.30pm)
Recruitment venue:
Raffles Executive Medical Centre (Level 12)
585 North Bridge Rd, Level 12 Raffles Hospital, Singapore 188770
Scan QR code or contact us at 6718 4737 to book an appointment!
Leave a Comment